Regimen That Reduces Cranial Radiation, HSCT Yields Promising Outcomes in ALL-T11
Researchers sought to determine the efficacy of a combination nelarabine, intensified L-asparaginase, and protracted intrathecal therapy among patients with ALL-T11.
Diagnosis & Disease Information
Adding Venetoclax Does Not Improve PFS vs Ibrutinib and Obinutuzumab in Untreated Older Patients With CLL
Researchers investigated whether adding venetoclax to ibrutinib and obinutuzumab would improve survival and allow for discontinuation of treatment in older patients with CLL.
Inotuzumab Ozogamicin, Blinatumomab May Be Superior to Chemotherapy in Some Elderly Patients With B-Cell ALL
Researchers sought to determine if a chemotherapy-free regimen including inotuzumab ozogamicin and blinatumomab would be effective in elderly patients with B-cell ALL.
MRD Assessment Improves Risk-Based Treatment in Patients With Pediatric ALL
Researchers sought to determine whether assessment of MRD using flow cytometry would improve risk stratification in pediatric ALL.
Outcomes Appear Poor After CD19-Directed CAR-T Therapy Relapse in Children With B-ALL
Researchers sought to determine long-term outcomes in children after relapse following CD19-directed CAR-T therapy for B-ALL.
Haploidentical vs Matched Unrelated Donor Age Impacts Survival in Patients With ALL
Researchers sought to determine the impact of donor age on survival in patients with ALL who undergo HCT with PTCy for GVHD prophylaxis.
Quizartinib Plus Chemotherapy Improves Survival vs Placebo in FLT3-ITD-Positive AML
Researchers sought to determine whether adding quizartinib to standard chemotherapy would improve survival in patients with newly diagnosed FLT3-ITD-positive AML.
Clinicogenomic Analysis Confirms Poor Outcomes in T-ALL After Induction Failure
Researchers sought to determine whether a clinicogenomic analysis of T-ALL would be able to confirm poor outcomes despite treatment with chemotherapy and HSCT.
Substantial Proportion of Patients With MDS or AML Not Considered for HCT
Researchers sought to determine the proportion of potentially eligible patients with high-risk MDS or AML who are considered for HCT.
Clinical Indicators Associated With Arsenic-Induced Hepatotoxicity in APL
Researchers sought to determine clinical indicators that are associated with ATO-induced hepatotoxicity in patients with APL.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...